A major component of the insulin resistance syndrome is dyslipidemia. Alterations in serum lipid levels can be worsened by insulin resistance and represent a leading risk factor for the ...

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

Besides the multiple mechanisms for atherogenesis accompanying the lipid triad, atherogenic dyslipidemia commonly is associated with several nonlipid risk factors as part of the insulin resistance ...